SPECIAL NOTICE
A -- Identification, Characterization and Development of Inhibitors That Act on Proteins Involved in Modulating Pro-oncogenic Processes.
- Notice Date
- 3/10/2004
- Notice Type
- Special Notice
- NAICS
- 541710
— Research and Development in the Physical, Engineering, and Life Sciences
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Bldg 427, Room 12, Frederick, MD, 21702
- ZIP Code
- 21702
- Archive Date
- 5/1/2004
- Point of Contact
- Bonnie Chamberlain, Marketing Coordinator, Phone (301)435-3134, Fax (301)402-2117, - Bonnie Chamberlain, Marketing Coordinator, Phone (301)435-3134, Fax (301)402-2117,
- E-Mail Address
-
chamberbo@mail.nih.gov, chamberbo@mail.nih.gov
- Description
- Summary: The National Cancer Institute (NCI) is currently seeking a Collaborator for a Cooperative Research and Development Agreement (CRADA) to work with investigators in the Center for Cancer Research (CCR), the Medical Oncology Clinical Research Unit (MOCRU), to select protein binding sites on targets involved in modulating pro-oncogenic processes, discover novel small molecules to meet these binding site requirements, then synthesize and test these small molecule inhibitors for their efficacy in modulating pro-oncogenic processes. Proposed CRADA Collaborator Contribution: The Collaborator will use its proteomics and bio- and chemiinformatics capabilities to assess and analyze mutually agreed upon crystal structures of target proteins. The Collaborator will generate a drug design report and provide conceptual, representative structures of small molecule inhibitors that are recommended for synthesis. Upon synthesis and confirmation of activity of members of a novel series by NCI (or Collaborator), Collaborator may undertake co-crystallization of compounds and further apply proteomics and bio- and chemiinformatics for lead optimization. The Collaborator’s contribution may include submission of an IND to the FDA. Proposed NCI Contribution: The NCI (or Collaborator) may synthesize and NCI will test mutually agreed upon compounds and identify leads with suitable biological activity and acceptable ADME properties. NCI will conduct necessary preclinical and clinical studies to advance optimized molecules to IND status, and perform appropriate clinical trials required for product registration. NCI’s contribution may include submission of the IND to the FDA. Proposed Joint Contribution: NCI and the Collaborator will jointly design a CRADA research plan, will jointly interpret the data generated, and mutually agree on which compounds should enter clinical trials. Selection Criteria for Choosing the CRADA Collaborator May Include: 1. A demonstrated background and expertise in proteomics and bio- and chemiinformatics. 2. A demonstrated record of success in the commercial development and production of products related to this area of technology (for example, development of protein-based small molecule inhibitors). 3. The demonstration of adequate resources to perform the proteomics, small molecule design studies, and to perform the research and development (including crystallographic studies) necessary for commercialization of the resulting inventions. 4. The willingness to commit best effort and demonstrated resources to the research and development of targets for multiple carcinomas. 5. The level of financial and staffing support necessary for CRADA-related activities. 6. The willingness to cooperate with the NCI in the timely publication of research results. 7. The agreement to be bound by the appropriate Department of Health and Human Services (DHHS) regulations relating to human subject research and to all Public Health Service (PHS) policies relating to the use and care of laboratory animals. 8. The willingness to accept the legal provisions and language of the CRADA. These provisions govern the distribution of future patent rights to CRADA inventions. Generally, the rights of ownership are retained by the organization that is the employer of the inventor with (1) the grant of a license for research and other Government purposes to the Government when the CRADA Collaborator’s employee is the sole inventor, or (2) the grant of an option to elect an exclusive or nonexclusive license to the CRADA Collaborator when the Government employee is the sole inventor. Response Procedure: Interested parties should notify the Technology Transfer Branch of the NCI in writing of their interest in the CRADA collaboration no later than April 30, 2004. The written notice should briefly address the selection criteria listed above. Contact Information: CRADA Contact: Michelle A. Booden, Ph.D. 6120 Executive Boulevard, Suite 450 Rockville, Maryland 20852 301-451-2185 or 301-496-0477; FAX 301-402-2117 e-mail: boodenm@mail.nih.gov
- Web Link
-
Link to FedBizOpps document.
(http://www.eps.gov/spg/HHS/NIH/FCRF/Reference-Number-MB-1952/listing.html)
- Record
- SN00542175-F 20040312/040310233308 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |